Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico antes de ser publicado, versión del autor (Preprint)

ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA

  • Talamillo, A
  • Grande, L
  • Ruiz-Ontañon, P
  • Velasquez, C
  • Mollinedo, P
  • Torices, S
  • Sánchez-Gómez, Pilar
  • Aznar, A
  • Esparis-Ogando, A
  • Lopez-Lopez, C
  • Lafita, C
  • Berciano, M T
  • Montero, J A
  • Vazquez-Barquero, A
  • Segura, V
  • Villagra, N T
  • Pandiella, A
  • Lafarga, Miguel
  • Leon, J
  • Martinez-Climent, J A
  • Sanz-Moreno, V
  • Fernandez-Luna, J L
Long-term survival remains low for most patients with glioblastoma (GBM), which reveals the need for markers of disease outcome and novel therapeutic targets. We describe that ODZ1 (also known as TENM1), a type II transmembrane protein involved in fetal brain development, plays a crucial role in the invasion of GBM cells. Differentiation of glioblastoma stem-like cells drives the nuclear translocation of an intracellular fragment of ODZ1 through proteolytic cleavage by signal peptide peptidase-like 2a. The intracellular fragment of ODZ1 promotes cytoskeletal remodelling of GBM cells and invasion of the surrounding environment both in vitro and in vivo. Absence of ODZ1 by gene deletion or downregulation of ODZ1 by small interfering RNAs drastically reduces the invasive capacity of GBM cells. This activity is mediated by an ODZ1-triggered transcriptional pathway, through the E-box binding Myc protein, that promotes the expression and activation of Ras homolog family member A (RhoA) and subsequent activation of Rho-associated, coiled-coil containing protein kinase (ROCK). Overexpression of ODZ1 in GBM cells reduced survival of xenografted mice. Consistently, analysis of 122 GBM tumour samples revealed that the number of ODZ1-positive cells inversely correlated with overall and progression-free survival. Our findings establish a novel marker of invading GBM cells and consequently a potential marker of disease progression and a therapeutic target in GBM.
Repisalud
Publicación Artículo científico (JournalArticle)

Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma

  • Gonzalez-Gomez, Pilar
  • Crecente-Campo, Jose
  • Zahonero, Cristina
  • Fuente, Maria de la
  • Hernández-Laín, Aurelio
  • Mira, Helena
  • Sánchez-Gómez, Pilar
  • Garcia-Fuentes, Marcos
Glioblastoma tumor initiating cells are believed to be the main drivers behind tumor recurrence, and therefore therapies that specifically manage this population are of great medical interest. In a previous work, we synthesized controlled release microspheres optimized for intracranial delivery of BMP7, and showed that these devices are able to stop the in vitro growth of a glioma cell line. Towards the translational development of this technology, we now explore these microspheres in further detail and characterize the mechanism of action and the in vivo therapeutic potential using tumor models relevant for the clinical setting: human primary glioblastoma cell lines. Our results show that BMP7 can stop the proliferation and block the self-renewal capacity of those primary cell lines that express the receptor BMPR1B. BMP7 was encapsulated in poly (lactic-co-glycolic acid) microspheres in the form of a complex with heparin and Tetronic, and the formulation provided effective release for several weeks, a process controlled by carrier degradation. Data from xenografts confirmed reduced and delayed tumor formation for animals treated with BMP7-loaded microspheres. This effect was coincident with the activation of the canonical BMP signaling pathway. Importantly, tumors treated with BMP7-loaded microspheres also showed downregulation of several markers that may be related to a malignant stem cell-like phenotype: CD133(+), Olig2, and GFAPδ. We also observed that tumors treated with BMP7-loaded microspheres showed enhanced expression of cell cycle inhibitors and reduced expression of the proliferation marker PCNA. In summary, BMP7-loaded controlled release microspheres are able to inhibit GBM growth and reduce malignancy markers. We envisage that this kind of selective therapy for tumor initiating cells could have a synergistic effect in combination with conventional cytoreductive therapy (chemo-, radiotherapy) or with immunotherapy.
Repisalud
Publicación Artículo científico (JournalArticle)

Shoc2/Sur8 Protein Regulates Neurite Outgrowth

  • Leon-Espinosa, Gonzalo
  • Sanchez-Ruiloba, Lucia
  • Perez-Rodriguez, Andrea
  • Gragera, Teresa
  • Martinez, Natalia
  • Hernandez, Silvia
  • Anta-Felez, Berta
  • Calero, Olga
  • Garcia-Dominguez, Carlota A
  • Dura, Lara M
  • Peña-Jimenez, Daniel
  • Castro, Judith
  • Zarich-Dimitrievich, Natasha
  • Sánchez-Gómez, Pilar
  • Calero, Miguel
  • Iglesias, Teresa
  • Oliva-Martinez, Jose Luis
  • Rojas-Cabañeros, Jose Maria
The Shoc2 protein has been implicated in the positive regulation of the Ras-ERK pathway by increasing the functional binding interaction between Ras and Raf, leading to increased ERK activity. Here we found that Shoc2 overexpression induced sustained ERK phosphorylation, notably in the case of EGF stimulation, and Shoc2 knockdown inhibited ERK activation. We demonstrate that ectopic overexpression of human Shoc2 in PC12 cells significantly promotes neurite extension in the presence of EGF, a stimulus that induces proliferation rather than differentiation in these cells. Finally, Shoc2 depletion reduces both NGF-induced neurite outgrowth and ERK activation in PC12 cells. Our data indicate that Shoc2 is essential to modulate the Ras-ERK signaling outcome in cell differentiation processes involved in neurite outgrowth.
Repisalud
Publicación Artículo científico (JournalArticle)

Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.

  • Zahonero, Cristina
  • Aguilera, Pilar
  • Ramírez-Castillejo, Carmen
  • Pajares, Marta
  • Bolos, Victoria
  • Cantero, Diana
  • Pérez-Núñez, Ángel
  • Hernández-Laín, Aurelio
  • Sánchez-Gómez, Pilar
  • Sepúlveda, Juan Manuel
Glioblastomas (GBM) are devastating tumors in which there has been little clinical improvement in the last decades. New molecularly directed therapies are under development. EGFR is one of the most promising targets, as this receptor is mutated and/or overexpressed in nearly half of the GBMs. However, the results obtained with first-generation tyrosine-kinase inhibitors have been disappointing with no clear predictive markers of tumor response. Here, we have tested the antitumoral efficacy of a second-generation inhibitor, dacomitinib (PF299804, Pfizer), that binds in an irreversible way to the receptor. Our results confirm that dacomitinib has an effect on cell viability, self-renewal, and proliferation in EGFR-amplified ± EGFRvIII GBM cells. Moreover, systemic administration of dacomitinib strongly impaired the in vivo tumor growth rate of these EGFR-amplified cell lines, with a decrease in the expression of stem cell-related markers. However, continuous administration of the compound was required to maintain the antitumor effect. The data presented here confirm that dacomitinib clearly affects receptor signaling in vivo and that its strong antitumoral effect is independent of the presence of mutant receptor isoforms although it could be affected by the PTEN status (as it is less effective in a PTEN-deleted GBM line). Dacomitinib is being tested in second line for EGFR-amplified GBMs. We hope that our results could help to select retrospectively molecular determinants of this response and to implement future trials with dacomitinib (alone or in combination with other inhibitors) in newly diagnosed GBMs.
Repisalud
Publicación Artículo científico (JournalArticle)

DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis

  • Fernández-Martínez, P
  • Zahonero, Cristina
  • Sánchez-Gómez, Pilar
DYRK1A (dual-specificity tyrosine-regulated kinase 1A) is a kinase with multiple implications for embryonic development, especially in the nervous system where it regulates the balance between proliferation and differentiation of neural progenitors. The DYRK1A gene is located in the Down syndrome critical region and may play a significant role in the developmental brain defects, early neurodegeneration, and cancer susceptibility of individuals with this syndrome. DYRK1A is also expressed in adults, where it might participate in the regulation of cell cycle, survival, and tumorigenesis, thus representing a potential therapeutic target for certain types of cancer. However, the final readout of DYRK1A overexpression or inhibition depends strongly on the cellular context, as it has both tumor suppressor and oncogenic activities. Here, we will discuss the functions and substrates of DYRK1A associated with the control of cell growth and tumorigenesis with a focus on the potential use of DYRK1A inhibitors in cancer therapy.
Repisalud
Publicación Artículo científico (JournalArticle)

Cancer stem cells from human glioblastoma resemble but do not mimic original tumors after in vitro passaging in serum-free media

  • García-Romero, Noemí
  • González-Tejedo, Carmen
  • Carrión-Navarro, Josefa
  • Esteban-Rubio, Susana
  • Rackov, Gorjana
  • Rodríguez-Fanjul, Vanessa
  • Oliver-De La Cruz, Jorge
  • Prat-Acín, Ricardo
  • Peris-Celda, María
  • Blesa, David
  • Ramírez-Jiménez, Laura
  • Sánchez-Gómez, Pilar
  • Perona, Rosario
  • Escobedo-Lucea, Carmen
  • Belda-Iniesta, Cristobal
  • Ayuso-Sacido, Angel
Human gliomas harbour cancer stem cells (CSCs) that evolve along the course of the disease, forming highly heterogeneous subpopulations within the tumour mass. These cells possess self-renewal properties and appear to contribute to tumour initiation, metastasis and resistance to therapy. CSC cultures isolated from surgical samples are considered the best preclinical in vitro model for primary human gliomas. However, it is not yet well characterized to which extent their biological and functional properties change during in vitro passaging in the serum-free culture conditions. Here, we demonstrate that our CSC-enriched cultures harboured from one to several CSC clones from the human glioma sample. When xenotransplanted into mouse brain, these cells generated tumours that reproduced at least three different dissemination patterns found in original tumours. Along the passages in culture, CSCs displayed increased expression of stem cell markers, different ratios of chromosomal instability events, and a varied response to drug treatment. Our findings highlight the need for better characterization of CSC-enriched cultures in the context of their evolution in vitro, in order to uncover their full potential as preclinical models in the studies aimed at identifying molecular biomarkers and developing new therapeutic approaches of human gliomas.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Spatial patterns and drivers of SME digitalisation

  • Holl, Adelheid
  • Rama Dellepiane, Ruth
Digital transformation plays an increasingly important role in the growth and competitiveness of small and medium-sized enterprises (SMEs), yet little is known regarding spatial inequalities in their adoption of advanced digital technologies. Using recent data from the Flash Eurobarometer 486, we study the spatial patterns of drivers for the implementation of new digital technologies in SMEs in Europe. In our analysis, the focus is on the possible influence of location. Considerable heterogeneity of SMEs is found in their propensity to adopt advanced digital technologies related to the strength of the local business environment and to the urban/rural hierarchy, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

  • Uribe-Herranz, Mireia
  • Oliver-Caldés, Aina
  • Martínez-Micaelo, Neus
  • Español-Rego, Marta
  • Val-Casals, Maria
  • Martínez-Soler, Roberto
  • Rubio-Garcia, Elisa
  • Brunello, Valeria
  • Mihelic, Erik Z.
  • Klein-González, Nela
  • Benítez-Ribas, Daniel
  • Amigó, Núria
  • Vergara, Andrea
  • Ortiz-Maldonado, Valentín
  • Rodríguez-Lobato, Luis Gerardo
  • Delgado, Julio
  • Ortiz de Landazuri, Iñaki
  • González-Calle, Verónica
  • Cabañas, Valentín
  • Martín-Antonio, Beatriz
  • Pérez-Amill, Lorena
  • Reguera-Ortega, Juan Luis
  • Rodríguez-Otero, Paula
  • Paiva, Bruno
  • Martínez-López, Joaquín
  • Mateos, Maria Victoria
  • Pascal, Mariona
  • Urbano-Ispizúa, Álvaro
  • González-Navarro, Europa Azucena
  • Fernández de Larrea, Carlos
  • Juan, Manel
Multiple myeloma remains incurable despite advances in immunotherapies like chimeric antigen receptor (CAR) T-cell therapy. This study investigates the role of metabolites and gut microbiota in clinical outcomes in patients treated with the humanized B-cell maturation antigen (BCMA)-directed CAR-T therapy ARI0002h. Stool metabolites, particularly succinate, were associated with CAR T-cell phenotypes and persistence in patients. In CAR T-cell culture, succinate supplementation enhanced CD4+ central memory phenotype and respiratory capacity. In a murine myeloma model, a succinate-enhancing diet significantly improved CAR T-cell persistence and showed a trend toward better tumor control. Furthermore, Acidaminococcaceae, Monoglobaceae, or Akkermansiaceae, along with specific metabolites, were associated with CAR T-cell clinical outcomes. These multimodal profiles were integrated into response models, including one that identified patients likely to achieve a complete response by days 100 and 180 after infusion. These findings suggest that metabolites and gut microbiota correlate with CAR T-cell therapy responses and can be a valuable tool for risk assessment., This work has been partially supported by grants from the Instituto de Salud Carlos III (cofunded by the European Union), Spanish Ministry of Health (FIS PI18/00775, PICI18/00012 ICI19/00025, PI19/00669, PI22/00647, and complementary grant for CONCORD-023), Fondo Europeo de Desarrollo Regional “una manera de hacer Europa” 2021SGR01292 (AGAUR; Generalitat de Catalunya), “La Caixa” Foundation (CP042702/LCF/PR/GN18/50310007), RICORS-TERAV network (RD21/0017/0009 and RD21/0017/0019), Red de Terapia Celular (RD16/0011/0005), Centro de Investigación Biomédica en Red de Cáncer (CB16/12/00369 and CB16/12/00489), Asociación Española Contra el Cáncer (LABAE21971FERN), and Fundació Bosch I Aymerich., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Combined in-silico and on-chip validation of pseudopalisade formation hypothesis in Glioblastoma

  • Martínez-González, Alicia
  • Ayuso, Jose Maria
  • Monge, Rosa
  • Virumbrales-Muñoz, Maria
  • Llamazares, Guillermo A.
  • Hernández-Laín, A.
  • Sánchez-Gómez, Pilar
  • Pérez-García, Victor
  • Fernández, Luis
  • Ochoa, Ignacio
Introduction: Hypercellular regions surrounding necrotic areas in glioblastoma (GBM), named pseudopalisades, are characteristic of these tumors and have been hypothesized to be waves of migrating GBM cells. These structures are thought to be induced by oxygen depletion caused by the accumulation of cells far from nutrient supplies (chronic hypoxia) and/or tumor-induced blood vessel occlusion (acute hypoxia). The universal appearance of these structures in GBM suggests that they may play an instrumental role in their spreading and invasion. However the validation of the mechanisms of pseudopalisade formation has remained challenging. Materials and methods: A mathematical model was developed incorporating the main mechanisms of pseudopalisade formation. Oxygen coming from straight vessels drives phenotype changes. A third phenotype was included accounting for hypoxic cells switching back to a more proliferative phenotype in regions of normoxia. Experiments were done by embedding different densities of U-251 MG cells within a collagen hydrogel in a custom-designed microfluidic device. By controlling the medium flow through lateral microchannels, we mimic and control blood-vessel obstruction events associated with this disease. Results: Nutrient and oxygen starvation triggered a strong migratory process leading to pseudopalisade generation in silico and in vitro. Also, cells at greatest distance from oxygen supply became hypoxic after a critical point in tumor growth was reached (due to increased metabolism) forming pseudopalisades both in silico and in vitro. All the elements included in the mathematical model were necessary to describe both types of phenomena pointing out to the insufficiency of the go-or-grow hypothesis to describe pseudopalisade formation on-chip. Conclusions: Using a combination of computational and experimental techniques, we proved the feasibility of the two hypotheses of pseudopalisade formation, driven by either acute or chronic hypoxia. Additionally, we verified the potential of microfluidic devices as advanced artificial systems capable of experimentally modeling nutrient and oxygen gradients during tumor evolution.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor, Experience from an academic phase i clinical trial

  • Castellà, Maria
  • Caballero-Baños, M.
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • González-Navarro, Europa Azucena|||0000-0003-3310-5557
  • Suñé, Guillermo|||0000-0002-4034-4348
  • Antoñana Vildosola, Asier|||0000-0002-1404-6398
  • Boronat Barado, Anna
  • Marzal, Berta
  • Millán, Lucía
  • Martín-Antonio, B.|||0000-0003-0612-2693
  • Cid Colom, Jordi|||0000-0002-6406-0585
  • Lozano, Miquel|||0000-0003-2593-833X
  • García, E.
  • Tabera, Jaime|||0000-0002-5430-0151
  • Trias, E.
  • Perpiña, U.
  • Canals, Josep M.|||0000-0001-6829-7670
  • Baumann, Tycho|||0000-0003-4421-0088
  • Benítez Ribas, Daniel|||0000-0002-2346-5324
  • Campo, Elias|||0000-0001-9850-9793
  • Yagüe, Jordi|||0000-0001-8210-1929
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Rives, S.
  • Delgado, Julio|||0000-0002-5157-4376
  • Juan, Manel|||0000-0002-3064-1648
Development of semi-automated devices that can reduce the hands-on time and standardize the production of clinical-grade CAR T-cells, such as CliniMACS Prodigy from Miltenyi, is key to facilitate the development of CAR T-cell therapies, especially in academic institutions. However, the feasibility of manufacturing CAR T-cell products from heavily pre-treated patients with this system has not been demonstrated yet. Here we report and characterize the production of 28 CAR T-cell products in the context of a phase I clinical trial for CD19+ B-cell malignancies (NCT03144583). The system includes CD4-CD8 cell selection, lentiviral transduction and T-cell expansion using IL-7/IL-15. Twenty-seven out of 28 CAR T-cell products manufactured met the full list of specifications and were considered valid products. Ex vivo cell expansion lasted an average of 8.5 days and had a mean transduction rate of 30.6 ± 13.44%. All products obtained presented cytotoxic activity against CD19+ cells and were proficient in the secretion of pro-inflammatory cytokines. Expansion kinetics was slower in patient's cells compared to healthy donor's cells. However, product potency was comparable. CAR T-cell subset phenotype was highly variable among patients and largely determined by the initial product. T and T were the predominant T-cell phenotypes obtained. 38.7% of CAR T-cells obtained presented a TN or T phenotype, in average, which are the subsets capable of establishing a long-lasting T-cell memory in patients. An in-depth analysis to identify individual factors contributing to the optimal T-cell phenotype revealed that ex vivo cell expansion leads to reduced numbers of T, T, and T cells, while T cells increase, both due to cell expansion and CAR-expression. Overall, our results show for the first time that clinical-grade production of CAR T-cells for heavily pre-treated patients using CliniMACS Prodigy system is feasible, and that the obtained products meet the current quality standards of the field. Reduced ex vivo expansion may yield CAR T-cell products with increased persistence in vivo.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Ligand-based CAR-T cell, Different strategies to drive T cells in future new treatments

  • Ramírez-Chacón, Alejandro
  • Betriu-Méndez, Sergi|||0000-0002-4199-1168
  • Bartoló-Ibars, Ariadna
  • González, Azucena
  • Martí, Mercè|||0000-0002-1846-0043
  • Juan, Manel|||0000-0002-3064-1648
Chimeric antigen receptor (CAR)-based therapies are presented as innovative treatments for multiple malignancies. Despite their clinical success, there is scientific evidence of the limitations of these therapies mainly due to immunogenicity issues, toxicities associated with the infusion of the product, and relapses of the tumor. As a result, novel approaches are appearing aiming to solve and/or mitigate the harmful effects of CAR-T therapies. These include strategies based on the use of ligands as binding moieties or ligand-based CAR-T cells. Several proposals are currently under development, with some undergoing clinical trials to assess their potential benefits. In addition to these, therapies such as chimeric autoantibody receptor (CAAR), B-cell receptor antigen for reverse targeting (BAR), and even chimeric human leukocyte antigen (HLA) antibody receptor (CHAR) have emerged, benefiting from the advantages of antigenic ligands as antibody-binding motifs. This review focuses on the potential role that ligands can play in current and future antitumor treatments and in other types of diseases, such as autoimmune diseases or problems associated with transplantation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness

  • Bachiller, Mireia|||0000-0002-6153-4722
  • Pérez-Amill, Lorena|||0000-0003-0674-4660
  • Battram, Anthony M.|||0000-0002-9179-0639
  • Carné, Sebastian Ciro
  • Najjar, Amer M.
  • Verhoeyen, Els
  • Juan, Manel|||0000-0002-3064-1648
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Martín-Antonio, B.|||0000-0003-0612-2693
Background Chimeric antigen receptor (CAR)-T cell immunotherapy has modified the concept of treatment in hematological malignancies. In comparison with pediatric patients, where responses are maintained over many years, older patients, such as those with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM), present lower persistence of CAR-T cells that might be due to decreased fitness of T cells acquired with aging. Moreover, cord blood derived-NK cells (CB-NKs) and CAR-NK cells derived from CB-NK can be used ' off-the-shelf' as immune cells with antitumor properties for the treatment of cancer patients. However, to date, clinical studies have only demonstrated the safety of these therapies but not optimal efficacy. To confront the shortcomings of each therapy, we devised a novel approach consisting of simultaneous (CAR-)NK cell and CAR-T cell administration. In this setting, NK cells demonstrate an important immunoregulation of T cells that could be exploited to enhance the efficacy of CAR-T cells. Methods A combinatorial treatment based on either CAR-T and CAR-NK cells or CB-NK and CAR-T cells in two models of NHL and MM was performed. Antitumor efficacy was analyzed in vitro and in vivo, and parameters related to early activation, exhaustion and senescence of T cells were analyzed. Results We show that CAR-NK cells derived from CB-NK are only effective at high doses (high E:T ratio) and that their activity rapidly decreases over time in comparison with CAR-T cells. In comparison and to exploit the potential of ' off-the-shelf' CB-NK, we demonstrate that a low number of CB-NK in the CAR-T cell product promotes an early activation of CAR-T cells and their migration to MM cells leading to enhanced anti-MM efficacy. Moreover, cytokines related to CRS development were not increased, and importantly, CB-NK enhanced the fitness of both CAR pos and CAR neg T cells, promoting lower levels of exhaustion and senescence. Conclusion This study demonstrates a relevant immunoregulatory role of CB-NK collaborating with CAR-T cells to enhance their antitumor activity. A novel and different approach to consider in CAR-T cell immunotherapy studies is presented here with the goal to enhance the efficacy of the treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Corrigendum, Ligand-based CAR T-cell: Different strategies to drive T-cells in future new treatments